Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 LegoChem, Takeda Enter Next-Gen ADC Alliance | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

LegoChem, Takeda Enter Next-Gen ADC Alliance

Will apply ConjuAll technology platform to evaluate next-gen ADCs

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

LegoChem Biosciences (LCB), based in Daejeon South Korea, has entered into a research licensing agreement with Takeda Pharmaceuticals Co. to evaluate next-gen antibody drug conjugate (ADC) candidates. Takeda will have access to LCB’s ConjuAll, a next-gen ADC technology platform using a site-specific bio-conjugation method and a stable beta-glucuronide linker to design homogeneous plasma stable ADCs with the potential for improved payload delivery to cancer cells.

The companies will focus on evaluating novel ADC candidates and Takeda will have an exclusive option to license global rights to any project results.

Dr. Yong Zu Kim, president and chief executive officer of LCB said, “We are delighted that Takeda has recognized the potential of our proprietary ADC technology to address unmet medical needs in the ADC field. Takeda is a desirable partner for LCB as they have expertise and experience in the global commercialization of an antibody drug conjugate therapy.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics